Health Equity in Biomarker Testing and Targeted Therapy
Cancer biomarker testing can lead to targeted therapy which can improve survival and quality of life by connecting patients to the most beneficial treatment for their disease.
Recommendations for FDA's Office of Minority Health and Health Equity (OMHHE)
February 28, 2020
In response to a request from FDA, ACS CAN has provided recommendations for areas of focus for the Office of Minority Health and Health Equity (OMHHE). Recommendations include assessing the applicability of drug "snapshot" data, evaluating the appropriateness of aggregating racial groups for analysis, and examination of drug classes where differences in metabolism, safety or efficacy are likely to be seen.